Published in PLoS One on May 26, 2010
Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med (2011) 5.54
Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell (2012) 2.71
The resistance of intracellular mediators to doxorubicin and cisplatin are distinct in 3D and 2D endometrial cancer. J Transl Med (2012) 1.08
hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells. Oncogene (2015) 0.85
Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression. Oncotarget (2015) 0.81
LY294002 potentiates the anti-cancer effect of oxaliplatin for gastric cancer via death receptor pathway. World J Gastroenterol (2011) 0.79
Ligand-free estrogen receptor activity complements IGF1R to induce the proliferation of the MCF-7 breast cancer cells. BMC Cancer (2012) 0.78
Antiprogestins in gynecological diseases. Reproduction (2014) 0.78
AKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins. Sci Rep (2017) 0.75
Putting tumours in context. Nat Rev Cancer (2001) 12.37
Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol (1997) 10.61
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res (2005) 8.98
Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer (2005) 8.70
Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods (2007) 7.43
Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer (2009) 5.89
Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology. Proc Natl Acad Sci U S A (1998) 5.34
Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol (2005) 5.00
Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res (2005) 4.74
Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem (2001) 3.86
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov (2009) 3.64
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res (2009) 3.14
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev (2008) 3.13
Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation. J Biol Chem (1996) 2.99
Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells. J Cell Biol (2004) 2.93
Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res (2006) 2.86
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene (2003) 2.84
A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnol (2005) 2.77
Akt1 governs breast cancer progression in vivo. Proc Natl Acad Sci U S A (2007) 2.67
Unraveling the microenvironmental influences on the normal mammary gland and breast cancer. Semin Cancer Biol (2008) 2.41
Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res (2002) 2.37
HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat (2009) 2.34
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol (2007) 2.34
Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc Natl Acad Sci U S A (1995) 2.09
Suppression of mammary epithelial cell differentiation by the helix-loop-helix protein Id-1. Mol Cell Biol (1995) 1.97
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer (2005) 1.81
Stem cells in the etiology and treatment of cancer. Curr Opin Genet Dev (2005) 1.80
Targeting the tumor microenvironment. Front Biosci (2007) 1.72
Analysis of cycloheximide-induced apoptosis in human leukocytes: fluorescence microscopy using annexin V/propidium iodide versus acridin orange/ethidium bromide. Cell Biol Int (2006) 1.68
Breast cancer by proxy: can the microenvironment be both the cause and consequence? Trends Mol Med (2008) 1.60
Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity. Am J Pathol (2007) 1.53
A novel 3D in vitro culture model to study stromal-epithelial interactions in the mammary gland. Tissue Eng Part C Methods (2008) 1.45
Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. Carcinogenesis (2007) 1.35
Roles of AKT signal in breast cancer. Front Biosci (2007) 1.33
Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics. Cancer Res (2007) 1.31
Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model. Cancer Res (2008) 1.28
Fulvestrant (Faslodex) -- how to make a good drug better. Oncologist (2007) 1.28
Collagen-IV and laminin-1 regulate estrogen receptor alpha expression and function in mouse mammary epithelial cells. J Cell Sci (2003) 1.27
New highlights on stroma-epithelial interactions in breast cancer. Breast Cancer Res (2004) 1.19
Staged stromal extracellular 3D matrices differentially regulate breast cancer cell responses through PI3K and beta1-integrins. BMC Cancer (2009) 1.17
Mitogen-activated protein kinase inhibition in traumatic brain injury: in vitro and in vivo effects. J Cereb Blood Flow Metab (2002) 1.15
Carcinoma-associated fibroblasts activate progesterone receptors and induce hormone independent mammary tumor growth: A role for the FGF-2/FGFR-2 axis. Int J Cancer (2008) 1.10
Five novel hormone-responsive cell lines derived from murine mammary ductal carcinomas: in vivo and in vitro effects of estrogens and progestins. Cancer Res (2001) 1.02
The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. Endocr Relat Cancer (2009) 0.99
Mouse mammary tumors induced by medroxyprogesterone acetate: immunohistochemistry and hormonal receptors. J Natl Cancer Inst (1987) 0.99
The relevance of mouse models to understanding the development and progression of human breast cancer. J Mammary Gland Biol Neoplasia (2008) 0.96
Induction of mammary adenocarcinomas by medroxyprogesterone acetate in BALB/c female mice. Cancer Lett (1986) 0.95
Estradiol-induced regression in T47D:A18/PKCalpha tumors requires the estrogen receptor and interaction with the extracellular matrix. Mol Cancer Res (2009) 0.93
Reversal of antiprogestin resistance and progesterone receptor isoform ratio in acquired resistant mammary carcinomas. Breast Cancer Res Treat (2008) 0.92
Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res (1989) 0.90
p21, p27 and p53 in estrogen and antiprogestin-induced tumor regression of experimental mouse mammary ductal carcinomas. Carcinogenesis (2002) 0.90
Malignant mammary cells acquire independence from extracellular context for regulation of estrogen receptor alpha. Clin Cancer Res (2004) 0.88
Involvement of matrix metalloproteinase activity in hormone-induced mammary tumor regression. Am J Pathol (2006) 0.87
Establishment of an in vitro estrogen-dependent mouse mammary tumor model: a new tool to understand estrogen responsiveness and development of tamoxifen resistance in the context of stromal-epithelial interactions. Breast Cancer Res Treat (2008) 0.86
Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J Med Chem (2000) 0.84
Regulation of cell growth of a progestin-dependent murine mammary carcinoma in vitro: progesterone receptor involvement in serum or growth factor-induced cell proliferation. J Steroid Biochem Mol Biol (2000) 0.84
Estrogen or antiprogestin treatment induces complete regression of pulmonary and axillary metastases in an experimental model of breast cancer progression. Carcinogenesis (2005) 0.84
A spontaneous estrogen dependent, tamoxifen sensitive mouse mammary tumor: a new model system to study hormone-responsiveness in immune competent mice. Breast Cancer Res Treat (2008) 0.83
Progesterone receptor expression in medroxyprogesterone acetate-induced murine mammary carcinomas and response to endocrine treatment. Breast Cancer Res Treat (2003) 0.81
Phosphoinositide 3-kinase targeting by the beta galactoside binding protein cytokine negates akt gene expression and leads aggressive breast cancer cells to apoptotic death. Breast Cancer Res (2009) 0.79
Inhibition of mammary tumor growth by estrogens: is there a specific role for estrogen receptors alpha and beta? Breast Cancer Res Treat (2009) 0.78
Carcinoma-associated fibroblasts activate progesterone receptors and induce hormone independent mammary tumor growth: A role for the FGF-2/FGFR-2 axis. Int J Cancer (2008) 1.10
Estrogen receptor alpha mediates progestin-induced mammary tumor growth by interacting with progesterone receptors at the cyclin D1/MYC promoters. Cancer Res (2012) 1.00
Antiprogestins in breast cancer treatment: are we ready? Endocr Relat Cancer (2012) 1.00
The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. Endocr Relat Cancer (2009) 0.99
Interaction between FGFR-2, STAT5, and progesterone receptors in breast cancer. Cancer Res (2011) 0.95
Reversal of antiprogestin resistance and progesterone receptor isoform ratio in acquired resistant mammary carcinomas. Breast Cancer Res Treat (2008) 0.92
Association of estrogen receptor-alpha and progesterone receptor A expression with hormonal mammary carcinogenesis: role of the host microenvironment. Breast Cancer Res (2007) 0.91
p21, p27 and p53 in estrogen and antiprogestin-induced tumor regression of experimental mouse mammary ductal carcinomas. Carcinogenesis (2002) 0.90
NK cells expressing a progesterone receptor are susceptible to progesterone-induced apoptosis. J Immunol (2008) 0.90
Involvement of matrix metalloproteinase activity in hormone-induced mammary tumor regression. Am J Pathol (2006) 0.87
PI3K/AKT pathway regulates phosphorylation of steroid receptors, hormone independence and tumor differentiation in breast cancer. Carcinogenesis (2011) 0.85
Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters. Int J Cancer (2014) 0.84
Estrogen or antiprogestin treatment induces complete regression of pulmonary and axillary metastases in an experimental model of breast cancer progression. Carcinogenesis (2005) 0.84
Novel human breast cancer cell lines IBH-4, IBH-6, and IBH-7 growing in nude mice. J Cell Physiol (2009) 0.83
Hypermethylation of the progesterone receptor A in constitutive antiprogestin-resistant mouse mammary carcinomas. Breast Cancer Res Treat (2010) 0.83
Establishment of two hormone-responsive mouse mammary carcinoma cell lines derived from a metastatic mammary tumor. Breast Cancer Res Treat (2004) 0.82
Progesterone receptor expression in medroxyprogesterone acetate-induced murine mammary carcinomas and response to endocrine treatment. Breast Cancer Res Treat (2003) 0.81
Antisense oligonucleotides targeting the progesterone receptor inhibit hormone-independent breast cancer growth in mice. Breast Cancer Res (2005) 0.81
α(2)-Adrenoceptors enhance cell proliferation and mammary tumor growth acting through both the stroma and the tumor cells. Curr Cancer Drug Targets (2011) 0.81
Novel, low cost, highly effective, handmade steroid pellets for experimental studies. PLoS One (2013) 0.81
Classical membrane progesterone receptors in murine mammary carcinomas: agonistic effects of progestins and RU-486 mediating rapid non-genomic effects. Breast Cancer Res Treat (2010) 0.80
The effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancer. Oncotarget (2014) 0.80
Evidence for two progesterone receptor binding sites in murine mammary carcinomas. J Steroid Biochem Mol Biol (2003) 0.80
Associated expressions of FGFR-2 and FGFR-3: from mouse mammary gland physiology to human breast cancer. Breast Cancer Res Treat (2011) 0.79
Cytogenetic characterization of the murine bladder cancer model MB49 and the derived invasive line MB49-I. Cancer Genet (2012) 0.78
Differential effects of raloxifene, tamoxifen and fulvestrant on a murine mammary carcinoma. Breast Cancer Res Treat (2003) 0.78
Inhibition of mammary tumor growth by estrogens: is there a specific role for estrogen receptors alpha and beta? Breast Cancer Res Treat (2009) 0.78
[The role of estrogen receptor alpha in breast cancer cell proliferation mediated by progestins]. Medicina (B Aires) (2012) 0.77
Karyotypic evolution of four novel mouse mammary carcinoma cell lines. Identification of marker chromosomes by fluorescence in situ hybridization. Cancer Genet Cytogenet (2003) 0.77
MPA-induced gene expression and stromal and parenchymal gene expression profiles in luminal murine mammary carcinomas with different hormonal requirements. Breast Cancer Res Treat (2010) 0.77
Inoculated mammary carcinoma-associated fibroblasts: contribution to hormone independent tumor growth. BMC Cancer (2010) 0.77
Cytogenetic findings, Trp53 mutations, and hormone responsiveness in a medroxyprogesterone acetate induced murine breast cancer model. Cancer Genet Cytogenet (2005) 0.77
Targeting progesterone receptors in breast cancer. Vitam Horm (2013) 0.76
[Extra nuclear localization of steroid receptors and non genomic activation mechanisms]. Medicina (B Aires) (2010) 0.76
Mifepristone inhibits MPA-and FGF2-induced mammary tumor growth but not FGF2-induced mammary hyperplasia. Medicina (B Aires) (2010) 0.76
Action of hexachlorobenzene on tumor growth and metastasis in different experimental models. Toxicol Appl Pharmacol (2013) 0.76
Isolation of a stromal cell line from an early passage of a mouse mammary tumor line: a model for stromal parenchymal interactions. J Cell Physiol (2005) 0.75